Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075582 · ClinicalTrials.gov registry record · Phase 3
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
NCT00075582 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 390 participants.
The verdict
NCT00075582, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
Study Summary
This phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective in treating low-risk rhabdomyosarcoma.
Interventions
- DRUG cyclophosphamide
- PROCEDURE conventional surgery
- RADIATION radiation therapy
- DRUG vincristine sulfate
- DRUG dactinomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2004-09-04 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075582
The ClinicalTrials.gov registry entry for NCT00075582 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00075582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075582 about?
NCT00075582 is a clinical study titled "Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma". This phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop tumor cells from divi...
What is the current status of trial NCT00075582?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 2004-09-04. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT00075582?
The interventions under investigation include: cyclophosphamide (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), vincristine sulfate (DRUG), dactinomycin (DRUG).
Who is sponsoring clinical trial NCT00075582?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.